Navigation Links
Blood cell researcher wins science academy's 2013 Gottschalk Medal
Date:1/15/2013

Walter and Eliza Hall Institute researcher Dr Benjamin Kile has been awarded the Australian Academy of Science's 2013 Gottschalk Medal for a series of major discoveries that have shed new light on blood cell formation and function.

The Gottschalk Medal, named in honour of biochemist Dr Alfred Gottschalk, recognises outstanding research in the medical sciences by researchers less than 40 years of age.

Dr Kile, a laboratory head in the institute's Cancer and Haematology division, said he was honoured to be awarded the Gottschalk Medal. "I love what I do, and it has been a privilege to be able to pursue a career in medical research in Australia," Dr Kile said. "This award is recognition for work that has involved literally dozens of colleagues and collaborators, here at the Walter and Eliza Hall Institute, nationally and internationally".

Dr Kile's work has centred on understanding the genes that are essential for the formation and function of blood cells and blood stem cells.

One of Dr Kile's best-known discoveries was that platelets, tiny cells essential for blood clotting, are born with a short, predetermined lifespan and when their biological clock runs out, they are programmed to commit suicide. This finding solved a 100-year-old mystery about platelet biology and has implications for blood transfusions and cancer treatment.

"Our research team showed platelets have an internal programmed cell death pathway that tells them when to die, rather than dying as a result of external factors," Dr Kile said. "This raises the prospect of extending the life span of blood bank platelets by inhibiting the cell death pathway; increasing the availability of this life-saving product for cancer patients and others in danger of serious bleeding," Dr Kile said. "It also has implications for understanding conditions where platelets cause unwanted blood clots, such as heart disease and stroke, which are two of the biggest killers in Australia today."

In 2008 Dr Kile and his colleagues also made the discovery that a gene called ERG, which is involved in prostate cancer and leukaemia, is a master regulator of blood stem cell function. Identifying the targets of ERG may ultimately lead to new cancer therapies.

"Everybody knew the Erg gene was highly oncogenic (cancer-causing) it is one of the most commonly rearranged genes in human cancer but we didn't know what its day job was," Dr Kile said. "Our research showed that Erg is essential for maintaining and regulating blood stem cells, which underpin the body's blood and immune systems. This immediately suggested an explanation for Erg's profound oncogenicity; cancers acquire a lot of characteristics of stem cells, so the fact it is switched on in tumours suddenly made sense."

Institute director Professor Doug Hilton said Dr Kile's discoveries, while having basic biological significance, have also directly informed clinical practice, and have the potential to lead to new therapeutics.

"Ben has shown a willingness to pursue the translational implications of his work to a remarkable degree," Professor Hilton said. "He has already cemented his international standing as one of the brightest young stars of blood cell research, and his career trajectory remains resolutely upwards."


'/>"/>
Contact: Penny Fannin
fannin@wehi.edu.au
61-393-452-345
Walter and Eliza Hall Institute
Source:Eurekalert  

Related medicine news :

1. Infection Might Raise Blood Clot Risk for Older Adults: Study
2. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
3. Common Blood Pressure Drug Safe for Heart Failure: Study
4. Certain Birth Control Pills May Carry Higher Blood Clot Risk: FDA
5. High Blood Pressure May Be Especially Lethal for Blacks
6. Changes in gene expression may help explain high blood pressure in pregnancy
7. Researchers Develop Blood Test for Depression
8. Naturopathic care can improve blood sugar, mood in diabetes
9. Diabetes Groups Issue New Guidelines on Blood Sugar
10. Exercise May Help Patients With High Blood Pressure Live Longer
11. Additional blood pressure screening may reduce incidence of CVD events and death by up to 3 percent
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Blood cell researcher wins science academy's 2013 Gottschalk Medal
(Date:2/14/2016)... ... February 14, 2016 , ... ... of Heart Failure Nurses (AAHFN) is promoting healthier living with heart failure by ... of Life! Healthy Living with Heart Failure will kick-off February 14 and includes ...
(Date:2/13/2016)... ... February 13, 2016 , ... ... Voices of Recovery, the leading national organization representing the growing community of recovering ... public office to include Family Recovery in policies addressing addiction. , Although ...
(Date:2/13/2016)... ... February 13, 2016 , ... In ... states that vein visualization technology should be used to ensure patient safety when ... world, the INS Standards mandate the use of vein visualization technology in patients ...
(Date:2/13/2016)... ... , ... DDi , a Makro company, makes it ... expertise in eClinical Solutions. DDi has built its solution competency with a unique ... clients. DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains by ...
(Date:2/12/2016)... WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH ... for low-resource settings. The partnership will recruit top students from U.S. universities ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Va. , Feb. 12, 2016   National ... Hoey , RPh, MBA issued the following statement today ... released by the Centers for Medicare & ... raised by NCPA, beneficiary advocates and others: ... raised. We are still reviewing the full CMS analysis. ...
(Date:2/12/2016)... , Feb. 12, 2016 Hypermarcas ... a cash tender offer (the "Tender Offer") to ... outstanding aggregate principal amount of its 6.500% Senior ... ISIN Nos. US44915JAA88/ USP5246AAF05) (the "Notes"). In connection ... (the "Consent Solicitation") consents (the "Consents") of the ...
(Date:2/12/2016)... -- Innophos Holdings, Inc. (NASDAQ: IPHS ), a leading international ... it will host a live conference call on Tuesday, February ... quarter and full year 2015 results. ... quarter and full year results will be issued on Monday, ... --> --> The conference call can be ...
Breaking Medicine Technology: